Fania 2011.

Clinical features and settings	Study period: n.r. Patient population: 11 patients with recurrent INSS stage 4 neuroblastoma previously treated with first line therapy according European protocol NB‐HR 01. Consecutive series: n.r. Diagnostic work‐up: n.r. Time spans symptoms‐index test, symptoms‐reference standard and index test‐reference standard: n.r. Treatment between index test‐reference standard: n.r.
Participants	Included patients: 11 patients with recurrent neuroblastoma. Mediang age: n.r.; mean age was 10.8 years (range 3 to 15 years). Sex distribution: 7 boys (64%), 4 girls (36%). INSS stage: all stage 4.
Study design	Cohort study. N.r. whether the study was retrospective or prospective.
Target condition and reference standard(s)	Target condition: recurrent INSS stage 4 neuroblastoma. Reference standard of the primary tumour: n.r. Reference standard of metastases: histopathology (bone marrow aspirates and trephine biopsies), clinical imaging, or both.
Index and comparator tests	Index test: FDG‐PET scintigraphy. Comparator test: MIBG scintigraphy. Radiofarmacon: FDG‐PET and MIBG. Dose: n.r. Equipment: n.r. Acquisition protocol:n.r. Acquisition time: n.r. Acquisition duration: n.r. Interfering medication: n.r. Thyroid prophylaxis: n.r. Positive test result: n.r. Number and expertise of observers: n.r. Interobserver concordance: n.r.
Follow‐up	n.r.
Notes	Not published in full‐text (as of December 2012), but presented at the EANM 2011. It was n.r. which tracers were used for MIBG‐ and FDG‐PET scintigraphy. We could not get in contact with the authors.